Shenzhen Jikang Pharmaceutical Technology

Shenzhen Jikang Pharmaceutical Technology is a China-based biotechnology company focused on the research and development of small molecule drugs to treat aging-related and metabolic diseases. Established in 2017, the company utilizes a specialized discovery platform to identify compounds that modulate pathways involved in cellular senescence and metabolic homeostasis. Its lead programs target high-prevalence conditions such as non-alcoholic steatohepatitis (NASH), Alzheimer's disease, and sarcopenia. Jikang Pharmaceutical is positioned within the emerging longevity biotech sector, aiming to extend healthy lifespan through pharmacological intervention. The firm is supported by leading domestic investors, including Shenzhen Capital Group and Green Pine Capital Partners.